Global Head and Neck Cancer Therapeutics Market Report 2022: Immunotherapy Against Autoimmune Disorders Drives Sector Growth – ResearchAndMarkets.com


DUBLIN–(BUSINESS WIRE)–Added Head and Neck Cancer Therapeutics: Global Markets report ResearchAndMarkets.com Offer.

This report aims to provide a comprehensive study of the global Head and Neck Cancer Therapeutics market, both in terms of quantitative and qualitative data, to assist companies in developing growth strategies, evaluating the market landscape, their positions to analyze the current market and make informed business decisions related to head and neck cancer therapeutics.

An in-depth analysis of the global Head and Neck Cancer Therapeutics Market includes historical data and market forecasts on sales by diagnostic method type, treatment type, disease indication, route of administration, therapeutic class and end user. It describes the different types of head and neck cancer (lip and oral cavity cancer, larynx cancer, oropharyngeal cancer, salivary gland cancer, nasopharyngeal cancer and hypopharyngeal cancer) and their current and historical market revenues. This report also categorizes the global head and neck cancer therapeutics market based on route of administration (injectable and oral).

For a deeper understanding of the market, the report profiles the competitive landscape, key competitors and their respective market shares. The report also discusses the pipeline analysis and the new regulatory landscape of the marketed drugs.

report includes

  • A comprehensive overview of the global Head and Neck Cancer Therapeutics markets within the industry

  • Analyzes of the global market trends with historical market sales data for 2020 and 2021, estimates for 2022 and projections of compound annual growth rates (CAGRs) up to 2027

  • Estimation and forecast of the true Head and Neck Cancer Therapeutics market size and related market share analysis by diagnostic method, treatment type, disease indication, route of administration, therapeutic class, end-user and region

  • To assess the key driving factors, opportunities and challenges in this innovation-driven market, with a focus on the impact of COVID-19 on the Head and Neck Cancer Therapeutics Market

  • Discussing the industry value chain analysis, which envisages a systematic investigation of the key intermediaries involved, with a focus on new product development, the regulatory scenario, and reimbursement and pricing factors

  • In-depth information on increasing investment in R&D activities, key technology issues, industry-specific challenges, and key types of end-use markets

  • Market share analysis of the major market players in the global pharmaceutical industry, their research priorities, product portfolios, pipeline products, and corporate competitive landscape

market dynamics

market leader

  • Immunotherapy against autoimmune diseases

  • Rising incidence of cancer worldwide

  • Advances in biochemistry and genomics

  • High unmet need

market challenges

  • Shortage of oncology professionals

  • High cost of biological therapies

Main topics covered:

Chapter 1 Introduction

Chapter 2 Summary and Highlights

Chapter 3 Market and Technology Background

Chapter 4 Regulatory Structure

Chapter 5 Market Breakdown by Diagnostic Method

Chapter 6 Market Breakdown by Treatment Type

Chapter 7 Market Breakdown by Disease Indication

Chapter 8 Market Breakdown by Route of Administration

Chapter 9 Market Breakdown by Therapeutic Class

Chapter 10 Market Breakdown by End User

Chapter 11 Market Dynamics

Chapter 12 Impact of Covid-19 on the market

Chapter 13 Pipeline Analysis

Chapter 14 Competitive Landscape

Chapter 15 Company Profiles

companies mentioned

  • Abbvie Inc.

  • Astrazeneca plc

  • Bayer AG

  • Bristol Myers Squibb

  • Eli Lilly and Co.

  • F. Hoffmann-La Roche AG

  • Pfizer Inc.

  • Merck & Co.

  • Sanofi-Aventis

For more information about this report, visit https://www.researchandmarkets.com/r/4gzd1u



Source link

READ:  Stretched oil refining capacity to keep global fuel markets fragile